(MENAFN- GlobeNewsWire - Nasdaq) The rheumatoid arthritis therapeutics market is set for growth driven by innovative biosimilars like Cyltezo and Hyrimoz, approved for multiple inflammatory conditions. The demand for targeted biologics and DMARDs is rising due to efficacy and safety advancements, presenting significant opportunities for pharmaceutical companies.Dublin, Sept. 26, 2025 (GLOBE NEWSWIRE) -- The "Rheumatoid Arthritis Therapeutics Market Size, Share & Trends Analysis Report by Molecule (Pharmaceuticals, Biopharmaceuticals), by Sales Channel (Prescription, Over-the-Counter), by Region, and Segment Forecasts, 2025-2033" report has been added to ResearchAndMarkets's offering.
The global rheumatoid arthritis therapeutics market size was estimated at USD 25.76 billion in 2024 and is projected to reach USD 41.42 billion by 2033, growing at a CAGR of 5.56% from 2025 to 2033. The introduction of innovative therapeutics for rheumatoid arthritis (RA) is playing a key role in boosting market growth.
![]()
The launch of new biosimilars such as Cyltezo, Hyrimoz, Amgevita, Erelzi, Avsola, and Rituximab by leading pharmaceutical companies including Amgen Inc., Pfizer Inc., Genentech, Inc., and Novartis has significantly reshaped the RA treatment landscape. For instance, In May 2024, Boehringer Ingelheim announced that the U.S. Food and Drug Administration had approved a high-concentration, citrate-free formulation of Cyltezo (adalimumab-adbm) the company's interchangeable biosimilar to Humira for treating multiple chronic inflammatory diseases including rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, psoriatic arthritis, hidradenitis suppurativa, ankylosing spondylitis, moderate-to-severe plaque psoriasis, and non-infectious uveitis.
In a similar development, January 2023 saw Novartis AG secure marketing authorization from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for Sandoz's citrate-free, high-concentration formulation (HCF) of Hyrimoz (adalimumab). This approval extends to all indications of the reference medicine, including RA, uveitis, ulcerative colitis, and plaque psoriasis. These next-generation biologics and biosimilars are designed to act on specific immune system molecules or receptors responsible for joint pain and inflammation, resulting in improved treatment outcomes. Rising demand for such targeted and efficient therapies is expected to further drive advancements in biologic treatments for RA.
In recent years, RA treatment strategies have shifted toward newer molecules capable of inducing disease remission. This evolution stems from a deeper understanding of RA's underlying mechanisms, leading to the creation of targeted biologic and synthetic disease-modifying antirheumatic drugs (DMARDs). While first-line treatment still includes small-molecule DMARDs, corticosteroids, analgesics, and nonsteroidal anti-inflammatory drugs (NSAIDs), these options primarily slow disease progression and manage inflammation rather than curing the condition. Moreover, they can cause notable side effects, such as gastrointestinal ulcers, immunosuppression, osteoporosis, nausea, cytopenia, fatigue, skin rashes, liver damage, psoriasis, and an increased risk of infections.
Why should you buy this report?
Comprehensive Market Analysis: Gain detailed insights into the industry across major regions and segments. Competitive Landscape: Explore the market presence of key players. Future Trends: Discover the pivotal trends and drivers shaping the future of the market. Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
Market intelligence to enable effective decision-making Market estimates and forecasts from 2018 to 2030 Growth opportunities and trend analyses Segmental and regional revenue forecasts for market assessment Competition strategy and market share analysis Product innovation listings for you to stay ahead of the curve COVID-19's impact and how to sustain in these fast-evolving markets
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 150 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value (USD) in 2024 | $25.76 Billion |
| Forecasted Market Value (USD) by 2033 | $41.42 Billion |
| Compound Annual Growth Rate | 5.5% |
| Regions Covered | Global |
Companies Featured
AbbVie, Inc. Boehringer Ingelheim International GmbH Novartis AG Regeneron Pharmaceuticals Inc. Pfizer, Inc. Bristol-Myers Squibb Company F. Hoffmann-La Roche Ltd. UCB S.A. Johnson & Johnson Services, Inc. Amgen, Inc. Lilly (Eli Lilly and Company)
Global Rheumatoid Arthritis Therapeutics Market Report Segmentation
Molecule Outlook (Revenue, USD Million, 2021-2033)
Pharmaceuticals NSAIDs Analgesics DMARDs Glucocorticoids Biopharmaceuticals Biologics T-cell inhibitors CD20 antigen JAK inhibitors Anti-IL6 biologics Biosimilars CD20 antigen TNF-a antagonists
Sales Channel Outlook (Revenue, USD Million, 2021-2033)
Prescription Over-the-Counter (OTC)
Regional Outlook (Revenue, USD Million, 2021-2033)
North America U.S. Canada Mexico Europe UK Germany France Italy Spain Denmark Sweden Norway Asia-Pacific Japan China India Australia South Korea Thailand Latin America Brazil Argentina Middle East & Africa South Africa Saudi Arabia UAE Kuwait
For more information about this report visit
About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Rheumatoid Arthritis Therapeutics Market
CONTACT:
CONTACT:
Laura Wood,Senior Press Manager
...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
![]()
MENAFN26092025004107003653ID1110115726
Comments
No comment